- Raised $1.2M grant, Mar 2009
- Raised $750k funding round, Jan 2007
About
Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. The companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.
Funding history · 2 rounds · $1.9M total
Q&A
- What is Biokine Therapeutics' primary focus?
- Biokine Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drugs to treat cancer, with a specialization in anticancer and stem cell mobilization drugs.
- When was Biokine Therapeutics founded and by whom?
- Biokine Therapeutics was founded in July 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital.
- What is Biokine Therapeutics' lead drug candidate?
- The company's lead drug candidate is BKT140/BL8040, a high-affinity CXCR4 antagonist.
- What clinical trials is BKT140/BL8040 currently undergoing?
- BKT140/BL8040 is currently in a Phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), and a Phase 1 clinical trial for the mobilization of stem cells.
- Has Biokine Therapeutics licensed BKT140/BL8040 to another company?
- Yes, BKT140/BL8040 was licensed to BioLineRx Ltd.
- How many employees does Biokine Therapeutics have?
- Biokine Therapeutics has 1-10 employees.
- What is the total amount of funding Biokine Therapeutics has raised?
- Biokine Therapeutics has raised a total of $1,950,000.
- When was Biokine Therapeutics' most recent funding round and what type was it?
- The company's most recent funding round was a Grant in March 2009, with funding from the Office of the Chief Scientist.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biokine.com |
|---|---|
| linkedin.com/company/5550255 | |
| Wikidata | wikidata.org/wiki/Q104480071 |
Identifiers & details
| Founded | 2000-7 |
|---|---|
| Employees (exact) | 4 |
| Wikidata QID | Q104480071 |
Radar intelligence
Patents
| EPO | 29 |
|---|
Web history (Wayback)
| Domain | biokine.com |
|---|
Wikidata
| QID | Q104480071 |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|